Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atrasentan Phase 2b in Diabetic Nephropathy
NCT01399580Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atrasentan in diabetic nephropathy (DN) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Change from baseline in log-transformed Urinary Albumin to Creatinine Ratio at 8 weeks. Started Aug 2011; status: completed.
02
Drugs
atrasentan
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT01399580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01399580.